AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today the publication of data in Molecular Therapy, the journal of the American Society of Gene Therapy, highlighting the results of a preclinical study with INGN 241 in combination with Avastin® (Bevacizumab). Synergistic activity resulting in a curative therapeutic effect was seen in the treatment of lung cancer following the combination of the two agents. In contrast, treatment with Avastin alone demonstrated only minor tumor regression and no animals were cured of their cancer. The study was conducted at The University of Texas M.D. Anderson Cancer Center by Introgen’s collaborator Dr. Rajagopal Ramesh, associate professor, Department of Thoracic and Cardiovascular Surgery.
